Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
Open Access
- 8 November 2022
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 197 (1) , 189-200
Abstract
Purpose: The status of human epidermal growth factor receptor 2 (HER2) is important for treatment decision-making of breast cancer and was commonly determined by core needle biopsy (CNB). The concordance of CNB with surgical excision biopsy (SEB) has been verified, but remain unclear according to the newly developed classification of HER2 status. Our study aimed to re-evaluate the diagnostic value of CNB for determining HER2 status in breast cancer, especially in the HER2-low population. Methods: Eligible breast cancer patients in West China Hospital between January 1, 2007 and December 31, 2021 were enrolled consecutively and data were extracted from the Hospital Information System. The agreement of HER2 status between CNB and SEB was calculated by concordance rate and κ statistics, as well as the sensitivity, specificity, positive, and negative predictive values (PPV & NPV). Logistic models were used to explore potential factors associated with the discordance between both tests. Results: Of 1829 eligible patients, 1097 (60.0%) and 1358 (74.2%) were consistent between CNB and SEB by pathological and clinical classifications, respectively, with κ value being 0.46 (0.43–0.49) and 0.57 (0.53–0.60). The sensitivity (50.9%–52.7%) and PPV (50.5%-55.2%) of CNB were especially low among IHC 1+ and 2+/ISH - subgroups by pathological classifications; however, it showed the highest sensitivity (77.5%) and the lowest specificity (73.9%) in HER2-low population by clinical classifications. Advanced N stages might be a stable indicator for the discordance between both tests. Conclusion: The diagnostic value of CNB was limited for determining HER2 status in breast cancer, especially in HER2-low population.Keywords
Funding Information
- National Natural Science Foundation of China (32071284)
- West China Hospital, Sichuan University (2022HXFH021)
- National Clinical Center for Geriatrics, West China (Z20192011)
This publication has 35 references indexed in Scilit:
- Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatmentScientific Reports, 2016
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast CancerAmerican Journal of Clinical Pathology, 2013
- Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancerBMC Cancer, 2013
- Discordance in early breast cancer for tumour grade, Estrogen Receptor, Progesteron Receptors and Human Epidermal Receptor-2 status between core needle biopsy and surgical excisional primary tumourThe Breast, 2011
- A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expressionThe American Journal of Surgery, 2011
- Breast Cancer Hormone Receptor Assay Results of Core Needle Biopsy and Modified Radical Mastectomy Specimens From the Same PatientsClinical Breast Cancer, 2010
- Systematic Review: Comparative Effectiveness of Core-Needle and Open Surgical Biopsy to Diagnose Breast LesionsAnnals of Internal Medicine, 2010
- Preoperative Profiling of Symptomatic Breast Cancer by Diagnostic Core BiopsyAnnals of Surgical Oncology, 2006
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989